Entod Pharmaceuticals has received marketing authorization from the Central Drugs Standard Control Organisation (CDSCO) for 0.05% atropine eye drops (Myatroo XL) developed to slow the progression of myopia in children aged 6 to 12. According to Entod, the treatment will be available by prescription for children diagnosed with myopia. Myatroo XL will be available in India in July.